- General Drug Summary
- Description
- Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water.
- Also Known As
- Colestyramine
- Categories
- Cholesterol Absorpti
- Structure
- Summary In Neonatal Jaundice
-
1 record(s) for Cholestyramine Effective in Maintaining Remission in Neonatal Jaundice.
- PMID
- Drug Name
- Efficacy
- Evidence
- 626526
- Cholestyramine
- Effective in Maintaining Remission
- Clinical Trial
- Summary
- Use of cholestyramine made it possible to shorten the daily duration of phototherapy in a case of congenital nonobstructive, nonhaemolytic jaundice.
- Case of congenital nonobstructive, nonhaemolytic jaundice. Successful long-term phototherapy at home. Archives of disease in childhood, 1978 Jan [Go to PubMed]
- Use of cholestyramine made it possible to shorten the daily duration of phototherapy in a case of congenital nonobstructive, nonhaemolytic jaundice. Treatment at home was therefore possible, allowing normal parental care. Development and neurological examinations were normal at the age of 27 months. Frequent determinations of reserve bilirubin binding capacity may be useful in controlling such management.
-
8 record(s) for Cholestyramine Effective in Inducing Remission in Neonatal Jaundice.
- PMID
- Drug Name
- Efficacy
- Evidence
- 7196459
- Cholestyramine
- Effective in Inducing Remission
- Clinical Trial
- Summary
- Intrahepatic cholestasis was responsible for persistent conjugated hyperbilirubinemia after birth. This responded favorably to cholestyramine therapy.
- Fetal intrahepatic cholestasis secondary to BO hemolytic disease. Journal of the National Medical Association, 1981 Aug [Go to PubMed]
- A rare occurrence of severe, direct hyperbilirubinemia in an infant with BO incompatibility was noted at four hours of age. Severe fetal hemolysis and markedly elevated indirect bilirubin levels might have caused induction of conjugating enzymes during fetal life in this case. Intrahepatic cholestasis was responsible for persistent conjugated hyperbilirubinemia after birth. This responded favorably to cholestyramine therapy.
- 3687022
- Cholestyramine
- Effective in Inducing Remission
- Clinical Trial
- Summary
- An anion exchange resin, used for the treatment of cholestatic pruritus
- [Value of cholescintigraphy in the differential diagnosis of direct hyperbilirubinemia in infancy]. Wiener klinische Wochenschrift, 1987 Sep 25 [Go to PubMed]
- Cholescintigraphy using 99mTc-diethyl-, 99mTc-diisopropyl-, 99mTc-iodo-diethyl- and 99mTc-bro-motrimethyl-IDA was performed in 22 newborns and infants with direct hyperbilirubinaemia. Retrospective evaluation of 99mTc-diethyl- and 99mTc-diisopropyl-IDA (n = 18) showed an efficiency of 66% in the differentiation between extrahepatic biliary atresia and neonatal intrahepatic diseases if the hepatocyte-clearance index and transit time were taken into consideration; the sensitivity of detecting extrahepatic biliary atresia was 100%. Cholestyramine treatment (n = 9) did not increase the efficiency of the test. Efficiency was markedly reduced when the serum direct bilirubin level was above 5.5 mg/dl (94 mumol/l). The gall bladder was not visualized in 13 out of 18 examinations. The prospective and retrospective analysis of 99mTc-iodo-diethyl- and 99mTc-bromo-trimethyl-IDA revealed intrahepatic disease in all 6 infants with serum values up to 12.6 mg/dl (216 mumol/l) direct bilirubin; the gall bladder was not visuaized in 4 out of 7 examinations.
- 3323894
- Cholestyramine
- Effective in Inducing Remission
- Clinical Trial
- Summary
- May increase the efficiency in the differential diagnosis of extrahepatic biliary atresia .
- [Value of percutaneous blind liver biopsy in preoperative diagnosis of atresia of the extrahepatic bile ducts]. Monatsschrift Kinderheilkunde : Organ der Deutsche, 1987 Nov [Go to PubMed]
- During a period of 7 years the case histories of 60 infants with direct hyperbilirubinaemia were prospectively evaluated. At presentation the majority of infants had an age below 1 month. By close clinical follow-up of all infants including the observation of acholic stools (21 infants), quantitative estimations of lipoprotein X during cholestyramine therapy (17 infants), cholescintigraphy (20 infants) and percutaneous liver biopsy (17 infants) the efficiency of the preoperative diagnostic work-up reached 96.6%. Liver biopsies were carried out selectively in only 29.3% of all infants (47.6% in infants with acholic stools and 17.9% in infants with normal stools); their efficiency in the differential diagnosis of extrahepatic biliary atresia was 88.2%.
- 105912
- Cholestyramine
- Effective in Inducing Remission
- Clinical Trial
- Summary
- As the administration causes a marked decrease of serum LP-X in patients with patent extrahepatic bile ducts.
- Quantitative changes of serum lipoprotein-X after cholestyramine administration in infants with cholestatic biliary tract and liver disease. European journal of clinical investigation, 1978 Dec [Go to PubMed]
- Lipoprotein-X (LP-X) was determined before and after the administration of cholestyramine in fifty-five infants with persistent cholestatic jaundice to differentiate between intra- and extrahepatic disease. In twenty-seven infants with biliary atresia, serum LP-X prior to cholestyramine ranged from 0.87 to 11.42 g/l (mean: 3.43 g/l; the average concentration was significantly lower (P less than 0.001) in males. After cholestyramine, LP-X rose in twenty-three, remained the same in two, and decreased slightly in two infants. Serum LP-X was present in twenty of the twenty-eight infants with intrahepatic cholestasis prior to cholestyramine in concentrations from 0.84 to 14.19 g/l (mean: 3.13 g/l). After cholestyramine, LP-X decreased in all by an average of 78% (P less than 0.005). The other eight infants did not have LP-X before or after cholestyramine. This study shows that LP-X in the serum of infants with cholestatic jaundice indicates severe cholestasis, but is not itself diagnostic of biliary atresia. The ifferentiation of biliary atresia from other diseases is readily achieved, as the administration of cholestyramine for 2-3 weeks causes a marked decrease of serum LP-X in patients with patent extrahepatic bile ducts. The absence of serum LP-X excludes biliary atresia.
- 3673281
- Cholestyramine
- Effective in Inducing Remission
- Clinical Trial
- Summary
- For the treatment of cholestatic pruritus.
- [Quantitative determination of LP-X in the differential diagnosis and treatment of direct hyperbilirubinemia in infancy]. Zeitschrift für Kinderchirurgie : organ der Deuts, 1987 Aug [Go to PubMed]
- Quantitative measurements of serum concentrations of LP-X were performed in 45 newborn and infants. The changes of LP-X concentrations before and after a 2-3 weeks' course of cholestyramine therapy differentiated extrahepatic biliary atresia (n = 6) from other causes of neonatal liver disease with a sensitivity of 100%, a specificity of 78.6 to 84.6% and an efficiency of 81.3 to 86.7%. The efficiency was decreased in children with alcoholic stools (75-80%). Cholestyramine treatment of 3-7 days did not allow to diagnose all children with extrahepatic biliary atresia. However, the test was superior to a combination of single measurements of LP-X and GGT. The changes of LP-X concentrations in serum were influenced by the individual course of the disease but not by the synthetic function of the liver (as indicated by CHE activities) or by parenteral nutrition or bacterial infections. LP-X was a valuable parameter in the management of cholestyramine therapy in infants with liver diseases.
- 7160933
- Cholestyramine
- Effective in Inducing Remission
- Clinical Trial
- Summary
- cholestyramine show an increase in bilirubin adsorbed
- The adsorption of bilirubin from aqueous solution onto solid cholestyramine and polyvinylpyrrolidone. The International journal of artificial organs, 1982 Nov [Go to PubMed]
- Shifts in the visible spectrum of aqueous bilirubin (BR) resulting from the addition of soluble polyvinylpyrrolidone (PVP) suggest specific interactions. Hence, isotherms were determined for the adsorption of BR from aqueous solution onto solid, cross-linked PVP and onto cholestyramine (CA) (used as a reference adsorbent) at 0, 10, 20 and 25 degrees C. Although adsorption onto PVP reaches equilibrium values more rapidly than for CA, the latter adsorbent has a larger capacity. Furthermore the isotherms for PVP are independent of temperature while those for CA show an increase in BR adsorbed with an increase in temperature.
- 2102973
- Cholestyramine
- Effective in Inducing Remission
- Clinical Trial
- Summary
- Oral administration of cholestyramine produced a statistically significant decrease in serum bile acids and bilirubin in infants with intrahepatic cholestasis under 10 weeks of age.
- Value of bile acid determination for the diagnosis of neonatal jaundice. Materia medica Polona. Polish journal of medicine , [Go to PubMed]
- Serum concentrations of bile acids and bilirubin, and activity of alanine transferase and alkaline phosphatase as well as bile acid and bilirubin levels in duodenal contents were determined in 90 infants aged 1-44 weeks (including 49 under 10 weeks of age) admitted to hospital for prolonged jaundice. Infants with extrahepatic cholestasis were found to have statistically higher serum bile acid and bilirubin concentrations. Oral administration of cholestyramine produced a statistically significant decrease in serum bile acids and bilirubin in infants with intrahepatic cholestasis under 10 weeks of age. In 24 out of the 30 infants with biliary tract obstruction total absence of bile acids in the duodenal contents was demonstrated while in the others the concentration did not exceed 0.2 mmol/l. The mean bile acid concentration in infants with intrahepatic cholestasis was 2.81 mmol/l while in 8 infants out of the 60 bile acids were either absent or present in trace amounts. The method had an 84.4% sensitivity.
- 180917
- Cholestyramine
- Effective in Inducing Remission
- Review
- Summary
- A treatment to intrahepatic cholestasis and biliary atresia.
- Identification of the jaundiced infant who is likely to recover without surgical intervention. Annals of surgery, 1976 Jul [Go to PubMed]
- A series of 32 infants with persistant jaundice in whom an unequivocal differentiation between intrahepatic cholestasis and biliary atresia could not be made is reviewed. A protocol including Lipoprotein-X (LP-X) determinations before and after a short course of cholestyramine (CSM) was carried out in all. A fall in serum LP-X after CSM indicates the presence of patent extrahepatic bile ducts (even microscopic) which will function without benefit of hepatic portoenterostomy. A rise in LP-X levels after CSM means an atretic biliary system. The LP-X, CSM protocol was not able to differentiate between the anatomical variants of biliary atresia that may respond to hepatic portoenterostomy and those that will not. Patent bile ducts (even microscopic) in the porta hepatis and/or proximal hepatoduodenal ligament, which are in continuity with intrahepatic ducts, must be present if hepatic portoenterostomy is to be successful. None of our 12 infants undergoing hepatic portoenterostomy showed evidence of bile excretio after the procedure. Microscopic study of serial sections taken through the excised hepatoduodenal ligament tissues of these 12 infants revealed that none had anatomical findings conducive to the success of the operation.
-
1 record(s) for Cholestyramine NA in Neonatal Jaundice.
- PMID
- Drug Name
- Efficacy
- Evidence
- 9035206
- Cholestyramine
- NA
- Clinical Trial
- Summary
- Tc-99m disofenin CS after premedication with phenobarbital and cholestyramine is a convenient and reliable method of differentiating BA from neonatal hepatitis, with a diagnostic accuracy superior to that of US. However, US is the initial imaging procedure of choice in patients presenting with jaundice to rule out anatomic anomalies such as CC.
- Comparison technetium of Tc-99m disofenin cholescintigraphy with ultrasonography in the differentiation of biliary atresia from other forms of neonatal jaundice. Pediatric surgery international, 1997 [Go to PubMed]
- Technetium Tc-99m disofenin cholescintigraphy (CS) and ultrasonography (US) are two major clinical methods used in differentiating biliary atresia (BA) from neonatal jaundice. To compare the diagnostic utility of these two modalities, 66 patients with neonatal cholestasis (15 BA, 3 choledochal cyst (CC), 32 neonatal hepatitis, 13 prolonged jaundice, 2 total parenteral nutrition, and 1 sepsis) underwent Tc-99m disofenin CS and US. The diagnostic sensitivity, specificity, and accuracy of CS in differentiating BA from other forms of neonatal jaundice was 100%, 87.5%, and 90.5%, respectively, and for US 86.7%, 77.1%, and 79.4%, respectively. Tc-99m disofenin CS after premedication with phenobarbital and cholestyramine is a convenient and reliable method of differentiating BA from neonatal hepatitis, with a diagnostic accuracy superior to that of US. However, US is the initial imaging procedure of choice in patients presenting with jaundice to rule out anatomic anomalies such as CC.